TCR2 Therapeutics (TCRR +2.7%) will collaborate with the National Cancer Institute (NCI) on a Phase 1/2 clinical trial evaluating its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) (named TC-210 at present) as a cancer therapeutic agent against a protein called mesothelin that is overexpressed in certain cancers (e.g., mesothelioma, ovarian cancer, pancreatic adenocarcinoma).
NCI’s activities will be aimed at better understanding TC-210’s pharmacodynamics via translational studies, measuring potential biomarkers in treated patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.